Abstract
The activation and subsequent platelet aggregation plays a key role in the formation of arterial thrombosis and therefore is the key therapeutic target in the treatment of acute coronary syndromes. Dual antiplatelet therapy containing aspirin and P2Y12 ADP receptor antagonist forms currently the basis in acute ST – elevation myocardial infarction (STEMI) pharmacological treatment. Nevertheless, there is a wide variability in pharmacodynamic response to administration of clopidogrel, the most frequently used P2Y12 ADP receptor antagonist. High platelet reactivity after clopidogrel administration is associated with increased risk of in - stent thrombosis and points to the suitability of laboratory monitoring of antiplatelet therapy effectivity in clinical practice. Laboratory monitoring of antiplatelet therapy by ex vivo platelet function tests may help to identify individuals with poor antiplatlet response. Recently, there is growing number of data reporting a failure in antiplatelet response following clopidogrel administration, which is specifically associated with insulin resistance and diabetes mellitus. Prasugrel, a new, potent P2Y12 ADP receptor antagonist, provides faster and more consistent inhibition of platelet function compared with clopidogrel. Prasugrel therapy was repeatedly described as an effective method to overcome clopidogrel resistance and prasugrel resistance has not yet been reliably described. Article gives a review about prasugrel resistance and its role in acute coronary syndrome patients.
Highlights
The activation and subsequent platelet aggregation plays a key role in the formation of arterial thrombosis and is the key therapeutic target in the treatment of Acute Coronary Syndromes (ACS)
Thienopyridine clopidogrel given in the CURE study (Clopidogrel in Unstable Angina to Prevent Recurrent Events) in patients with ACS significantly reduced the incidence of cardiac death and nonfatal myocardial infarction or stroke compared with patients treated with aspirin alone [1]
High platelet reactivity after clopidogrel administration is associated with increased risk of stent thrombosis and other ischemic events [5,6]
Summary
The activation and subsequent platelet aggregation plays a key role in the formation of arterial thrombosis and is the key therapeutic target in the treatment of Acute Coronary Syndromes (ACS). High variability in antiplatelet response to clopidogrel administration, points to the suitability of laboratory monitoring of antiplatelet therapy efficacy in patients with acute coronary syndrome.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Hematology & Thromboembolic Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.